Bayer HealthCare submits VEGF Trap-Eye for new EU approval

Bayer HealthCare has filed for European regulatory approval of VEGF Trap-Eye as a therapy option for patients affected by macular oedema following central retinal vein occlusion (CRVO).

An application for marketing authorisation of the therapy has been submitted to the European Medicines Agency, based on positive data from phase III trials showing the benefits of the drug in this indication.

This comes after the drug was ratified last month for use as a treatment for neovascular age-related macular degeneration in Europe, where it will be sold under the name Eylea.

Bayer is also trialling the compound as a potential therapy for diabetic macular oedema and myopic choroidal neovascularisation.

Dr Kemal Malik, member of the Bayer HealthCare executive committee and head of global development, said: "We are confident that VEGF Trap-Eye has the potential to provide patients and physicians a new treatment option for macular oedema following CRVO."

Earlier this week, the company received EU regulatory approval for Jaydess, a new implantable contraceptive product.